Skip Nav Destination
To treat or not to treat, that is the NLPHL question
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Issue Archive
Table of Contents
EDITORIAL
BLOOD COMMENTARIES
CLINICAL TRIALS AND OBSERVATIONS
To treat or not to treat, that is the NLPHL question
Clinical Trials & Observations
PLENARY PAPER
CLINICAL TRIALS AND OBSERVATIONS
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
Clinical Trials & Observations
Sven Borchmann,Erel Joffe,Craig H. Moskowitz,Andrew D. Zelenetz,Ariela Noy,Carol S. Portlock,John F. Gerecitano,Connie L. Batlevi,Philip C. Caron,Pamela Drullinsky,Audrey Hamilton,Paul A. Hamlin, Jr,Steven M. Horwitz,Anita Kumar,Matthew J. Matasar,Alison J. Moskowitz,Colette N. Owens,M. Lia Palomba,Anas Younes,David J. Straus
REVIEW SERIES
HEMATOPOIESIS AND STEM CELLS
A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency
Kerstin B. Kaufmann,Laura Garcia-Prat,Qiang Liu,Stanley W. K. Ng,Shin-Ichiro Takayanagi,Amanda Mitchell,Erno Wienholds,Peter van Galen,Christian A. Cumbaa,Mike J. Tsay,Chiara Pastrello,Elvin Wagenblast,Gabriela Krivdova,Mark D. Minden,Eric R. Lechman,Sasan Zandi,Igor Jurisica,Jean C. Y. Wang,Stephanie Z. Xie,John E. Dick
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Clinical Trials & Observations
Philipp Karschnia,Justin T. Jordan,Deborah A. Forst,Isabel C. Arrillaga-Romany,Tracy T. Batchelor,Joachim M. Baehring,Nathan F. Clement,L. Nicolas Gonzalez Castro,Aline Herlopian,Marcela V. Maus,Michaela H. Schwaiblmair,Jacob D. Soumerai,Ronald W. Takvorian,Ephraim P. Hochberg,Jeffrey A. Barnes,Jeremy S. Abramson,Matthew J. Frigault,Jorg Dietrich
There is a Blood Commentary on this article in this issue.
LYMPHOID NEOPLASIA
TRANSPLANTATION
Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
Nico Gagelmann,Markus Ditschkowski,Rashit Bogdanov,Swann Bredin,Marie Robin,Bruno Cassinat,Rabia Shahswar,Felicitas Thol,Michael Heuser,Gerard Socié,Dietrich Beelen,Ioanna Triviai,Anita Badbaran,Nicolaus Kröger
There is a Blood Commentary on this article in this issue.
BLOOD WORK
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
Confocal image of human acute myeloid leukemia 8227 CD34+ CD38+ cells overexpressing the PAK4 inhibitor C3orf54/INKA1. INKA1 regulates G0 exit of leukemia stem cells by interfering with nuclear localization of PAK4 (red), with concomitant reduction of H4K16ac (green) and CDK6 (yellow; blue: DAPI [4',6-diamidino-2-phenylindole]) levels. See the article by Kaufmann et al on page 2198.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals